Nalaganje...
No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
BACKGROUND: Fingolimod (FTY) is a sphingosine 1 phosphate (S1P) agonist with significant effects on immune cell distribution used as an effective disease modifying therapy in multiple sclerosis (MS) patients. Animal studies have demonstrated that a dysregulation of egress of murine secretory Immungl...
Shranjeno v:
| izdano v: | Front Cell Dev Biol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7546410/ https://ncbi.nlm.nih.gov/pubmed/33102475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.567659 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|